These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22891286)

  • 21. Therapeutic efficacy against
    Baldwin SL; Reese VA; Larsen SE; Pecor T; Brown BP; Granger B; Podell BK; Fox CB; Reed SG; Coler RN
    Front Microbiol; 2022; 13():935444. PubMed ID: 36090093
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic Vaccines for Tuberculosis: An Overview.
    Bouzeyen R; Javid B
    Front Immunol; 2022; 13():878471. PubMed ID: 35812462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against
    Lee JM; Park J; Reed SG; Coler RN; Hong JJ; Kim LH; Lee W; Kwon KW; Shin SJ
    Virulence; 2022 Dec; 13(1):808-832. PubMed ID: 35499090
    [No Abstract]   [Full Text] [Related]  

  • 24. Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.
    Carpenter SM; Lu LL
    Front Immunol; 2022; 13():830482. PubMed ID: 35371092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. It Takes a Village: The Multifaceted Immune Response to
    Larsen SE; Williams BD; Rais M; Coler RN; Baldwin SL
    Front Immunol; 2022; 13():840225. PubMed ID: 35359957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Update on Tuberculosis Vaccines.
    Gopalaswamy R; Subbian S
    Methods Mol Biol; 2022; 2410():387-409. PubMed ID: 34914059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of CD4
    Costa DL; Amaral EP; Namasivayam S; Mittereder LR; Andrade BB; Sher A
    Front Cell Infect Microbiol; 2021; 11():672527. PubMed ID: 34235093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.
    Larsen SE; Reese VA; Pecor T; Berube BJ; Cooper SK; Brewer G; Ordway D; Henao-Tamayo M; Podell BK; Baldwin SL; Coler RN
    Sci Rep; 2021 Apr; 11(1):9040. PubMed ID: 33907221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved
    Adeagbo BA; Akinlalu AO; Phan T; Guderian J; Boukes G; Willenburg E; Fenner C; Bolaji OO; Fox CB
    ACS Omega; 2020 Dec; 5(48):31306-31313. PubMed ID: 33324841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis.
    Scriba TJ; Netea MG; Ginsberg AM
    Semin Immunol; 2020 Aug; 50():101431. PubMed ID: 33279383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection.
    Clemmensen HS; Knudsen NPH; Billeskov R; Rosenkrands I; Jungersen G; Aagaard C; Andersen P; Mortensen R
    Front Immunol; 2020; 11():585359. PubMed ID: 33240275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine strategies for the
    Sharan R; Kaushal D
    NPJ Vaccines; 2020; 5():95. PubMed ID: 33083030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.
    Afkhami S; Villela AD; D'Agostino MR; Jeyanathan M; Gillgrass A; Xing Z
    Front Immunol; 2020; 11():557809. PubMed ID: 33013927
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Back YW; Shin KW; Choi S; Park HS; Lee KI; Choi HG; Kim HJ
    Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32664238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.
    Schijns V; Fernández-Tejada A; Barjaktarović Ž; Bouzalas I; Brimnes J; Chernysh S; Gizurarson S; Gursel I; Jakopin Ž; Lawrenz M; Nativi C; Paul S; Pedersen GK; Rosano C; Ruiz-de-Angulo A; Slütter B; Thakur A; Christensen D; Lavelle EC
    Immunol Rev; 2020 Jul; 296(1):169-190. PubMed ID: 32594569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculosis vaccine development: from classic to clinical candidates.
    Li J; Zhao A; Tang J; Wang G; Shi Y; Zhan L; Qin C
    Eur J Clin Microbiol Infect Dis; 2020 Aug; 39(8):1405-1425. PubMed ID: 32060754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.
    Sable SB; Posey JE; Scriba TJ
    Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31666281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.
    Afkhami S; Lai R; D'agostino MR; Vaseghi-Shanjani M; Zganiacz A; Yao Y; Jeyanathan M; Xing Z
    J Infect Dis; 2019 Sep; 220(8):1355-1366. PubMed ID: 31198944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.
    Baldwin SL; Larsen SE; Ordway D; Cassell G; Coler RN
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007083. PubMed ID: 30763316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.